The Linked Clinical Trials committee meets annually in person to examine dozens of potential therapeutics; those that have the highest likelihood of successfully treating Parkinson’s(PD) are selected for advancement to clinical trials. LCT scientific committee members hail from some of the leading research organisations in the world and have extensive experience treating all facets of PD. 

This year amongst others the committee chose three drugs where promising new findings have been recently published: SalbutamolTrazodone and Nortriptyline.

See more about our Linked Clinical Trials programme here.